share_log

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45

b of A Securities维持对bridgebio pharma的买入评级,将目标股价上调至45美元
Benzinga ·  2024/11/25 05:10  · 评级/大行评级

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $42 to $45.

b of A 证券分析师杰夫·米查姆维持BridgeBio Pharma(纳斯达克股票代码:BBIO)的买入并将目标股价从42美元上调至45美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发